Accelerate Diagnostics, Inc. is an in vitro diagnostics company engaged in providing solutions that develop patient outcomes through the diagnosis of serious infections. The Company's in vitro diagnostic platform, the Accelerate Pheno system utilizes genotypic technology to identify (ID), infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (AST), which determines whether live bacterial or fungal cells are resistant or susceptible to a particular antibiotic. It detects and identifies pathogens directly from a single patient sample followed by antimicrobial susceptibility testing based on the identification results. The Accelerate PhenoTest BC Kit provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The Accelerate Pheno system features walk-away automation and consists of a fixed instrument and single-use test kit.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: N/A
- Symbol: NASDAQ:AXDX
- CUSIP: N/A
- Web: www.acceleratediagnostics.com
Capitalization:- Market Cap: $1.5148 billion
- Outstanding Shares: 52,034,000
Average Prices:- 50 Day Moving Avg: $28.00
- 200 Day Moving Avg: $25.29
- 52 Week Range: $19.20 - $30.45
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -30.67
- P/E Growth: -0.78
Sales & Book Value:- Annual Revenue: $612,999.00
- Price / Sales: 2,342.81
- Book Value: $1.33 per share
- Price / Book: 20.75
Profitability:- EBIDTA: ($63,330,000.00)
- Net Margins: -11,158.43%
- Return on Equity: -76.35%
- Return on Assets: -71.90%
Debt:- Current Ratio: 13.42%
- Quick Ratio: 12.59%
Misc:- Average Volume: 316,883 shs.
- Beta: 1.98
- Short Ratio: 22.58
Frequently Asked Questions for Accelerate Diagnostics (NASDAQ:AXDX)
What is Accelerate Diagnostics' stock symbol?
Accelerate Diagnostics trades on the NASDAQ under the ticker symbol "AXDX."
How were Accelerate Diagnostics' earnings last quarter?
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) posted its quarterly earnings results on Friday, May, 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.07. The business had revenue of $0.50 million for the quarter, compared to analyst estimates of $0.60 million. Accelerate Diagnostics had a negative return on equity of 76.35% and a negative net margin of 11,158.43%. View Accelerate Diagnostics' Earnings History.
When will Accelerate Diagnostics make its next earnings announcement?
What guidance has Accelerate Diagnostics issued on next quarter's earnings?
Accelerate Diagnostics updated its first quarter earnings guidance on Wednesday, May, 3rd. The company provided earnings per share guidance of ($0.27) for the period, compared to the Thomson Reuters consensus estimate of ($0.35). The company issued revenue guidance of $530000, compared to the consensus revenue estimate of $1.31 million.
Where is Accelerate Diagnostics' stock going? Where will Accelerate Diagnostics' stock price be in 2017?
3 brokerages have issued twelve-month price targets for Accelerate Diagnostics' stock. Their forecasts range from $25.00 to $34.00. On average, they expect Accelerate Diagnostics' stock price to reach $30.33 in the next year. View Analyst Ratings for Accelerate Diagnostics.
Who are some of Accelerate Diagnostics' key competitors?
Some companies that are related to Accelerate Diagnostics include Natus Medical Incorporated (BABY), Quidel Corporation (QDEL), ABAXIS (ABAX), Mazor Robotics (MZOR), Luminex Corporation (LMNX), GenMark Diagnostics (GNMK), LeMaitre Vascular (LMAT), Accuray Incorporated (ARAY), Pacific Biosciences of California (PACB), Corindus Vascular Robotics (CVRS), ViewRay (VRAY), Cytosorbents Corporation (CTSO), Alliance HealthCare Services (AIQ), Viveve Medical (VIVE), Fulgent Genetic (FLGT), IRIDEX Corporation (IRIX), Cogentix Medical (CGNT) and Neovasc (NVCN).
Who are Accelerate Diagnostics' key executives?
Accelerate Diagnostics' management team includes the folowing people:
- John Patience, Independent Chairman of the Board
- Lawrence Mehren, President, Chief Executive Officer, Director
- Steve Reichling, Chief Financial Officer
- Joan Martin, Executive Vice President & Head of Europe, Middle East, and Africa
- Ron Price, Senior Vice President and Head of Commercial Operations, Americas
- Tom Brown, Independent Director
- Mark C. Miller, Independent Director
- Jack W. Schuler, Independent Director
- Matthew W. Strobeck Ph.D., Independent Director
- Frank J M ten Brink, Independent Director
How do I buy Accelerate Diagnostics stock?
Shares of Accelerate Diagnostics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Accelerate Diagnostics' stock price today?
One share of Accelerate Diagnostics stock can currently be purchased for approximately $27.60.
MarketBeat Community Rating for Accelerate Diagnostics (NASDAQ AXDX)MarketBeat's community ratings are surveys of what our community members think about Accelerate Diagnostics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Earnings History for Accelerate Diagnostics (NASDAQ:AXDX)Earnings History by Quarter for Accelerate Diagnostics (NASDAQ AXDX)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2017 | | ($0.30) | | | | | N/A |  |
| 5/5/2017 | Q1 | ($0.34) | ($0.27) | $0.60 million | $0.50 million | View | Listen | |
| 2/27/2017 | Q4 2016 | ($0.35) | ($0.31) | $0.24 million | $0.04 million | View | Listen | |
| 11/9/2016 | Q3 2016 | ($0.35) | ($0.34) | | $0.02 million | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Accelerate Diagnostics (NASDAQ:AXDX)2017 EPS Consensus Estimate: ($1.29)
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 1 | ($0.34) | ($0.34) | ($0.34) |
| Q2 2017 | 1 | ($0.34) | ($0.34) | ($0.34) |
| Q3 2017 | 1 | ($0.31) | ($0.31) | ($0.31) |
| Q4 2017 | 1 | ($0.30) | ($0.30) | ($0.30) |
(Data provided by Zacks Investment Research)
Dividend History for Accelerate Diagnostics (NASDAQ:AXDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Accelerate Diagnostics (NASDAQ:AXDX)Insider Ownership Percentage: 51.40%
Institutional Ownership Percentage: 37.34%
Insider Trades by Quarter for Accelerate Diagnostics (NASDAQ:AXDX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 6/21/2017 | Steven Reichling | Insider | Sell | 30,000 | $28.90 | $867,000.00 | |
| 1/9/2017 | Lawrence Mehren | Insider | Sell | 400,068 | $19.00 | $7,601,292.00 | |
| 1/9/2017 | Matthew Strobeck | Director | Buy | 8,000 | $19.00 | $152,000.00 | |
| 6/30/2016 | Jack W Schuler | Director | Buy | 90,147 | $13.95 | $1,257,550.65 | |
| 6/14/2016 | Jack W Schuler | Director | Buy | 14,033 | $13.67 | $191,831.11 | |
| 6/13/2016 | Jack W Schuler | Director | Buy | 15,967 | $13.70 | $218,747.90 | |
| 6/10/2016 | Jack W Schuler | Director | Buy | 88,316 | $14.69 | $1,297,362.04 | |
| 6/9/2016 | Jack W Schuler | Director | Buy | 101,272 | $14.14 | $1,431,986.08 | |
| 5/20/2016 | Jack W Schuler | Director | Buy | 4,270 | $11.04 | $47,140.80 | |
| 5/17/2016 | Jack W Schuler | Director | Buy | 10,000 | $11.45 | $114,500.00 | |
| 5/16/2016 | Jack W Schuler | Director | Buy | 11,511 | $11.91 | $137,096.01 | |
| 5/13/2016 | Jack W Schuler | Director | Buy | 20,000 | $12.45 | $249,000.00 | |
| 2/9/2016 | Jack W Schuler | Director | Buy | 600,000 | $11.86 | $7,116,000.00 | |
| 2/8/2016 | Jack W Schuler | Director | Buy | 20,000 | $12.32 | $246,400.00 | |
| 2/5/2016 | Jack W Schuler | Director | Buy | 7,308 | $12.65 | $92,446.20 | |
| 2/4/2016 | Jack W Schuler | Director | Buy | 10,000 | $12.98 | $129,800.00 | |
| 2/3/2016 | Jack W Schuler | Director | Buy | 50,100 | $13.09 | $655,809.00 | |
| 2/2/2016 | Jack W Schuler | Director | Buy | 20,000 | $13.46 | $269,200.00 | |
| 1/21/2016 | Jack W Schuler | Director | Buy | 10,000 | $15.02 | $150,200.00 | |
| 12/10/2015 | Larry N Feinberg | Major Shareholder | Buy | 117,647 | $17.00 | $1,999,999.00 | |
| 11/5/2015 | Jack W Schuler | Director | Buy | 11,899 | $16.81 | $200,022.19 | |
| 11/4/2015 | Jack W Schuler | Director | Buy | 52,837 | $16.81 | $888,189.97 | |
| 10/22/2015 | Jack W Schuler | Director | Buy | 2,160 | $15.82 | $34,171.20 | |
| 9/29/2015 | Brink Frank Jm Ten | Director | Buy | 9,800 | $15.24 | $149,352.00 | |
| 8/26/2015 | Jack W Schuler | Director | Buy | 10,000 | $17.81 | $178,100.00 | |
| 8/25/2015 | Jack W Schuler | Director | Buy | 10,000 | $18.56 | $185,600.00 | |
| 4/17/2015 | Jack W Schuler | Director | Buy | 11,000 | $21.94 | $241,340.00 | |
| 3/19/2015 | Matthew Strobeck | Director | Buy | 2,000 | $22.04 | $44,080.00 | |
| 3/9/2015 | Jack W Schuler | Director | Buy | 22,584 | $17.18 | $387,993.12 | |
| 1/5/2015 | Jack W Schuler | Director | Buy | 18,000 | $18.93 | $340,740.00 | |
| 9/22/2014 | Jack W Schuler | Director | Buy | 2,588 | $16.44 | $42,546.72 | |
| 9/19/2014 | Jack W Schuler | Director | Buy | 32,411 | $16.67 | $540,291.37 | |
| 8/21/2014 | Jack W Schuler | Director | Buy | 2,900 | $16.79 | $48,691.00 | |
| 8/5/2014 | Larry N Feinberg | Major Shareholder | Buy | 11,835 | $15.92 | $188,413.20 | |
| 8/5/2014 | Matthew Strobeck | Director | Buy | 20,000 | $16.70 | $334,000.00 | |
| 8/4/2014 | Matthew Strobeck | Director | Buy | 20,000 | $16.70 | $334,000.00 | |
| 7/16/2014 | Larry N Feinberg | Major Shareholder | Buy | 20,000 | $21.54 | $430,800.00 | |
| 7/1/2014 | Jack W Schuler | Director | Buy | 8,698 | $25.70 | $223,538.60 | |
| 6/30/2014 | Jack W Schuler | Director | Buy | 10,000 | $26.09 | $260,900.00 | |
| 6/30/2014 | Larry N Feinberg | Major Shareholder | Buy | 20,000 | $25.72 | $514,400.00 | |
| 5/12/2014 | Larry N Feinberg | Major Shareholder | Buy | 297,618 | $16.80 | $4,999,982.40 | |
| 2/5/2014 | Larry N Feinberg | Major Shareholder | Buy | 8,554 | $24.78 | $211,968.12 | |
| 1/27/2014 | Larry N Feinberg | Major Shareholder | Buy | 16,307 | $13.09 | $213,458.63 | |
| 12/31/2013 | Larry N Feinberg | Major Shareholder | Buy | 84,081 | $12.29 | $1,033,355.49 | |
| 10/30/2013 | Larry N Feinberg | Major Shareholder | Buy | 10,000 | $12.95 | $129,500.00 | |
| 8/30/2013 | Larry N Feinberg | Major Shareholder | Buy | 16,001 | $9.76 | $156,169.76 | |
| 8/28/2013 | Larry N Feinberg | Major Shareholder | Buy | 158,445 | $9.80 | $1,552,761.00 | |
| 8/16/2013 | Jack W Schuler | Director | Buy | 78,494 | $7.88 | $618,532.72 | |
| 8/14/2013 | Jack W Schuler | Director | Buy | 413,090 | $8.04 | $3,321,243.60 | |
| 8/14/2013 | Larry N Feinberg | Major Shareholder | Buy | 36,814 | $7.24 | $266,533.36 | |
| 8/9/2013 | Larry N Feinberg | Major Shareholder | Buy | 35,168 | $7.30 | $256,726.40 | |
| 6/21/2013 | Larry N Feinberg | Major Shareholder | Buy | 114,250 | $8.00 | $914,000.00 | |
| 6/12/2013 | Larry N Feinberg | Major Shareholder | Buy | 7,175 | $8.41 | $60,341.75 | |
| 6/7/2013 | Larry N Feinberg | Major Shareholder | Buy | 45,508 | $8.33 | $379,081.64 | |
(Data available from 1/1/2013 forward)
Headline Trends for Accelerate Diagnostics (NASDAQ:AXDX)
Latest Headlines for Accelerate Diagnostics (NASDAQ:AXDX)
| Source: |
|
| Date | Headline |
|---|
 | Commit To Purchase Accelerate Diagnostics At $25, Earn 28.8% Annualized Using Options
www.nasdaq.com - July 21 at 5:51 PM |
 | Accelerate Diagnostics Schedules Call to Review Second Quarter 2017 Results for August 3rd - GlobeNewswire (press release)
globenewswire.com - July 18 at 10:47 PM |
 | Accelerate Diagnostics Schedules Call to Review Second Quarter 2017 Results for August 3rd
finance.yahoo.com - July 18 at 5:47 PM |
 | Accelerate Diagnostics, Inc. (AXDX) Lifted to "Buy" at BidaskClub
www.americanbankingnews.com - July 16 at 4:00 PM |
| ETFs with exposure to Accelerate Diagnostics, Inc. : July 14, 2017
finance.yahoo.com - July 14 at 6:08 PM |
| Accelerate Diagnostics, Inc. breached its 50 day moving average in a Bullish Manner : AXDX-US : July 12, 2017
finance.yahoo.com - July 12 at 4:50 PM |
| Zacks: Accelerate Diagnostics, Inc. (AXDX) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - July 10 at 2:30 PM |
 | Wireless Sensing Technologies Energize Oil and Gas Pipeline Monitoring Sector
www.marketwatch.com - July 9 at 4:17 PM |
| Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - July 4 at 5:56 PM |
| Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Rating Lowered to Hold at BidaskClub
www.americanbankingnews.com - July 1 at 7:32 PM |
| BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag
finance.yahoo.com - June 30 at 4:20 PM |
| Walgreens Boots-LabCorp Tie Up for Patient Service Centers
finance.yahoo.com - June 29 at 5:21 PM |
| Quest Diagnostics to Buy Outreach Lab Service in Cape Cod - Nasdaq
www.nasdaq.com - June 29 at 2:30 AM |
| Accelerate Diagnostics, Inc. breached its 50 day moving average in a Bearish Manner : AXDX-US : June 28, 2017
finance.yahoo.com - June 28 at 4:26 PM |
 | Thermo Fisher Gets FDA's PMA for Oncomine Dx Target Test
www.zacks.com - June 27 at 3:54 PM |
| 3 Reasons Why Accelerate Diagnostics (AXDX) is a Great Momentum Stock
finance.yahoo.com - June 27 at 3:54 PM |
| ConforMIS (CFMS) Gets FDA Approval for iTotal Hip System - Nasdaq
www.nasdaq.com - June 26 at 4:22 PM |
| Accelerate Diagnostics, Inc. (AXDX) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - June 23 at 11:28 PM |
| Why Investors Should Buy Align Technology (ALGN) Right Now - Nasdaq
www.nasdaq.com - June 23 at 9:25 PM |
| Insider Selling: Accelerate Diagnostics, Inc. (AXDX) Insider Sells 30,000 Shares of Stock
www.americanbankingnews.com - June 23 at 7:15 PM |
| Zacks: Accelerate Diagnostics, Inc. (AXDX) Receives Consensus Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - June 23 at 11:27 AM |
| Lantheus (LNTH) Scores a Strong Buy Right Now: Here's How
www.zacks.com - June 22 at 8:55 PM |
| Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How
www.zacks.com - June 22 at 3:52 PM |
| Lantheus (LNTH) Scores a Strong Buy Right Now: Here's How - Nasdaq
www.nasdaq.com - June 22 at 11:58 AM |
| Bio-Rad (BIO) Scores a Strong Buy Right Now: Here's How - Nasdaq
www.nasdaq.com - June 22 at 11:58 AM |
| Why Quest Diagnostics (DGX) is a Suitable Pick for Investors - Nasdaq
www.nasdaq.com - June 22 at 11:58 AM |
| Here's Why Henry Schein is Worth Adding to Your Portfolio
finance.yahoo.com - June 22 at 11:58 AM |
| Why Hold Strategy is Apt for Thermo Fisher (TMO) Stock Now
finance.yahoo.com - June 22 at 11:58 AM |
| Genomic Health Cancer Tests Strong, Operating Expenses a Woe - Nasdaq
www.nasdaq.com - June 21 at 4:40 PM |
| Medtronic CRT Devices Improve Therapy Delivery, Cut Costs - Nasdaq
www.nasdaq.com - June 21 at 4:40 PM |
| PAREXEL to Launch Connected Journey Data-Driven Services
finance.yahoo.com - June 20 at 4:24 PM |
| ResMed (RMD) at 52-Week High: What's Driving the Stock?
finance.yahoo.com - June 20 at 4:24 PM |
| Luminex (LMNX) Scores a Strong Buy Right Now: Here's How
finance.yahoo.com - June 20 at 4:24 PM |
| Hologic Receives Extended FDA Clearance for SculpSure in US
finance.yahoo.com - June 19 at 9:44 AM |
| Inogen (INGN) Scores a Strong Buy Right Now: Here's How
finance.yahoo.com - June 19 at 9:44 AM |
| Accelerate Diagnostics Sees Unusually High Options Volume (AXDX)
www.americanbankingnews.com - June 18 at 7:04 AM |
| Why Does Intuitive Surgical Score as a Strong Buy Right Now - Nasdaq
www.nasdaq.com - June 16 at 9:29 PM |
| DaVita (DVA) Rolls Out Alliance Site Network for CKD Trial - Nasdaq ... - Nasdaq
www.nasdaq.com - June 16 at 4:28 PM |
| ETFs with exposure to Accelerate Diagnostics, Inc. : June 15, 2017
finance.yahoo.com - June 15 at 10:36 PM |
| Abbott Laboratories Up on EPD & Buyouts, Pediatric Weak - Nasdaq
www.nasdaq.com - June 15 at 5:31 PM |
| Henry Schein Grows on Strategic Buyouts, Competition Rife - Nasdaq
www.nasdaq.com - June 15 at 5:31 PM |
| Here's Why Phibro Animal Health Is Worth Buying Right Now - Nasdaq
www.nasdaq.com - June 15 at 5:31 PM |
| LabCorp to Grow in Precision Med with Cancer Diagnostics Lab ... - Nasdaq
www.nasdaq.com - June 15 at 5:31 PM |
| Medtronic Resource Centre Opens for Diabetic People in Canada - Nasdaq
www.nasdaq.com - June 14 at 8:57 PM |
| FDA Passes Zimmer Biomet's (ZBH) Zhejiang Facility Issue - Nasdaq
www.nasdaq.com - June 14 at 3:55 PM |
| Accelerate Diagnostics, Inc. – Value Analysis (NASDAQ:AXDX) : June 14, 2017
finance.yahoo.com - June 14 at 3:55 PM |
| Becton (BDX) with FlowJo to Provide Cloud Platform Services
finance.yahoo.com - June 14 at 10:19 AM |
| FDA Passes Zimmer Biomet's (ZBH) Zhejiang Facility Issue
finance.yahoo.com - June 14 at 10:19 AM |
| Hill-Rom Rides High on Solid Prospects, Asia-Pacific a Drag
finance.yahoo.com - June 14 at 10:18 AM |
| Medtronic Resource Centre Opens for Diabetic People in Canada
finance.yahoo.com - June 14 at 10:18 AM |
Accelerate Diagnostics (AXDX) Chart for Saturday, July, 22, 2017
